Stock Price & Analysis

Based on the provided data and current market conditions, here's a concise analysis for RMD stock:

Technical Analysis

• Current pre-market price: $231.91 (+0.09%)
• RSI-14 at 42.22 indicates neutral momentum but slightly oversold
• MACD showing bearish momentum with -2.20 and negative histogram
• Price trading below both 5-day SMA ($232.51) and 20-day SMA ($240.71)

Support & Resistance Levels

• Key resistance: $241.41 (Fibonacci R1)
• Key support: $230.25 (Fibonacci S1)
• Price currently testing support level

Fundamental Strengths

• Strong financial metrics:
  • Gross margin: 55.68%
  • ROE: 22.70%
  • Healthy current ratio: 2.59
  • Low debt-to-equity: 14.54%

Revenue Segments

• Devices: 52.16% ($2.44B)
• Masks: 35.37% ($1.66B)

Recent Analyst Views

• Jarden maintains Buy rating with PT A$41.48
• UBS also issued Buy rating
• Wilsons recently downgraded to Hold

Recommendation: HOLD

The stock is currently showing mixed signals. While fundamentals remain strong with healthy margins and low debt, technical indicators suggest short-term weakness. The pre-market movement is minimal (+0.09%), and the stock is trading near support levels. Consider waiting for confirmation of trend reversal before initiating new positions.

Based on the available data and market analysis, here is the price prediction for RMD stock in 2025:

Technical Analysis

The technical indicators show RMD is currently in a consolidation phase with:

• RSI(14) at 42.22 indicating neutral momentum
• MACD showing bearish divergence (-2.20)
• Stock trading below its 20-day SMA ($240.71) and 60-day SMA ($239.63)

Price Target Analysis

Key support and resistance levels based on Fibonacci analysis:

• Strong support: $230.25
• Key resistance: $241.41
• Secondary resistance: $244.86

Fundamental Drivers

Recent catalysts that will influence 2025 price:

• Strong Q4 2024 results with revenue of $1.28B and net profit of $344.62M, showing significant YoY growth
• Positive analyst ratings with multiple "Buy" recommendations:
  • KeyBanc: $280 price target
  • Bank of America: Maintained Buy rating
  • UBS: Upgraded to Buy

2025 Price Prediction

Based on technical and fundamental analysis, RMD stock is expected to trade in the range of:

• Base case: $245-255 (8-12% upside)
• Bull case: $270-280 (18-22% upside)
• Bear case: $220-230 (4-8% downside)

The most likely scenario (60% probability) is the base case, supported by:

1. Strong fundamental growth in core business
2. Multiple analyst upgrades
3. Technical consolidation setting up for potential breakout

The S1 support level for RMD Stock is $229.17 ,The R1 resistant level for RMD Stock is $240.85.

As of the end of day on 2025-02-27, the price of RMD Stock was $230.01.

The target price for RMD Stock according to analyst rating is 274.89, with the highest price target at 295.00 and the lowest at 247.00. Analysts have a Moderate Buy rating on RMD Stock overall.

The market cap of RMD is $34.0B.

Based on the provided data and recent market developments, here's a comprehensive analysis of RMD's valuation:

Technical Analysis

The stock is currently showing bearish signals with:

• RSI-14 at 42.22 indicating neutral but weakening momentum
• MACD showing negative divergence (-2.20) with bearish histogram
• Trading below both 20-day (240.71) and 60-day (239.63) moving averages
• Currently near the lower Bollinger Band (217.08), suggesting potential oversold conditions

Fundamental Valuation

The stock appears overvalued based on several metrics:

Metric	2023 FY	Industry Avg
P/E	35.90x	~25x
EV/EBITDA	24.84x	~18x
P/S	7.63x	~4x
P/B	7.78x	~3x

Recent Performance & Catalysts

• Stock declined over 8% following disappointing earnings
• Currently consolidating around support level of $228.80
• Trading range established between $228.80 (support) and $258 (resistance)

Analyst Sentiment

Mixed analyst views recently:

• KeyBanc maintains Buy rating with $280 target
• RBC Capital maintains Hold rating with $238 target
• UBS maintains Hold with $255 target

Financial Health

Strong fundamentals but declining margins:

• Revenue growth: +18% YoY to $4.22B
• Net income growth: +15% YoY to $897.6M
• Declining gross margin: 54.79% vs 55.71% previous year
• Healthy current ratio: 3.12x

Conclusion

RMD appears overvalued at current levels based on:

1. Premium valuation multiples vs industry
2. Declining margins despite revenue growth
3. Technical weakness in price action
4. Mixed analyst sentiment

The stock may find support around $228.80, but upside appears limited until fundamentals improve or valuation becomes more attractive.

ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company’s segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers.

Based on the provided data and references, I'll analyze RMD's price prediction for 2030:

Technical Analysis

The current technical indicators show:

• RSI(14) at 42.22 indicates neutral momentum
• MACD showing bearish divergence (-2.20)
• Stock trading below its 20-day moving average of $240.71
• Currently in a downtrend after recent earnings disappointment

Fundamental Drivers

According to ResMed's 2030 strategy announcement:

• Targeting to help over 500 million people worldwide achieve their full health potential
• Focus on growing core sleep apnea business and expanding into adjacent markets
• Investing 7% of revenue in R&D to build integrated digital health ecosystem
• Strong market opportunity with 2.3 billion people having sleep/breathing issues

Growth Catalysts

• Expansion into broader sleep health market (860M insomnia sufferers)
• COPD market opportunity (480M patients)
• Digital health platform scaling (28M+ patients on AirView)
• New product innovations like AirTouch N30i mask

Price Target Analysis

Based on analyst projections:

• Conservative case: $271.22
• Base case: $283.53 (22.38% upside from current)
• Bullish case: $295.84

For 2030, the stock is projected to reach approximately $329.77, representing a ~42% increase from current levels. This forecast is supported by:

1. Industry leadership in sleep technology
2. Large addressable market opportunity
3. Strong R&D investment
4. Digital health ecosystem advantages
5. High-single digit revenue growth targets

Conclusion

RMD stock is expected to reach approximately $330 by 2030, driven by market expansion, product innovation, and digital health transformation. The projection assumes successful execution of their 2030 strategy and continued leadership in sleep health technology.

RMD has a total of 10140 employees.